Innovent Biologics Inc., a leading biopharmaceutical company specializing in oncology, autoimmune, cardiovascular and metabolic, and ophthalmology treatments, has announced the upcoming presentation of multiple clinical study results at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. Highlighting the event will be the oral presentation of the first Phase 3 study of mazdutide in Chinese adults with Type 2 Diabetes (T2D), known as DREAMS-1, scheduled for June 23. Additionally, numerous exploratory mechanism of action analyses of mazdutide and a preclinical study of the novel antibody-peptide conjugate IBI3030 will be featured in poster presentations on June 22. These presentations aim to further validate the differentiated profile of mazdutide as a next-generation GCG/GLP-1 dual receptor agonist.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.